Table 1.
Abnormality of the ufmylation-related genes in different cancers
| Cancer type | No. of cases | UBA5 | UFC1 | UFL1 | UfSP2 | UFM1 |
|---|---|---|---|---|---|---|
| Lung squamous cell carcinoma | 178 | 11.8% (A) | 7.3% (A) | 1.7% (M), 1.7% (D) | 5.6% (D) | 1.1% (D) |
| Lung adenocarcinoma | 230 | 1.7% (A) | 12.6% (A) | 0.9% (M), 0.9% (D) | 2.6% (D) | 0.4% (A),1.3 (D) |
| Breast invasive carcinoma | 974 | 0.9% (A) | 13.6% (A) | 1.1% (A) | 1.8% (D) | 1.7% (D), 0.3% (A) |
| Ovarian serous cystadenocarcinoma | 311 | 6.4% (A) | 5.5% (A) | 1% (A) | 3.2% (D) | 1% (D), 0.6% (A), 0.3% (M) |
| Uterine corpus endometrioid carcinoma | 240 | 1.3% (M) | 5% (A) | 3.8% (M) | 4.6% (M) | 0.4% (D) |
| Pancreatic adenocarcinoma | 109 | 1.8% (D) | 21.1% (A) | 7.3% (D) | 4.6% (D) | 1.8% (D), 1.8% (A) |
| Esophageal carcinoma | 92 | 8.7% (A) | 4.3% (A) | 1.1% (D) | 2.2% (A) | 1.1% (D) |
| Liver hepatocellular carcinoma | 193 | 15.5% (A) | 1.6% (D) | 3.6% (D) | 0.5% (D), 0.5% (A), 0.5% (M) | |
| Bladder urothelial carcinoma | 127 | 1.6% (A) | 18.9% (A) | 1.6% (M), 1.6% (D) | 2.4% (M) | 2.4% (D), 1.6% (A), 0.8% (M) |
| Sarcoma | 256 | 0.4% (A) | 6.6% (A) | 1.2% (A) | 3.9% (D) | 1.6% (A), 1.6% (D) |
| Lymphoid neoplasm diffuse large B-cell lymphoma | 48 | 4.2% (A) | 4.2% (A) | 14.6% (D) | 8.3% (D) | 4.2% (D), 2.1% (A) |
| Prostate adenocarcinoma | 420 | 1.7% (A) | 1.2% (D) | 12.9% (D) | 0.2% (D) | 11.9% (D) |
Note: Data were obtained from www.cbioportal.org in December 2015. Alterations with frequency >3% are highlighted in bold. UFM1, ubiquitin-fold modifier 1; UfSP, UFM1-specific protease; UBA5, ubiquitin-like modifier-activating enzyme 5; UFC1, UFM1-conjugating enzyme 1; UFL1, UFM1-specific ligase 1; A, amplification; D, deletion; M, mutation.